Recent Research Analysts’ Ratings Updates for Dyne Therapeutics (DYN)

Dyne Therapeutics (NASDAQ: DYN) has recently received a number of price target changes and ratings updates:

• 9/9/2026 – Dyne Therapeutics had its price target lowered by Morgan Stanley from $45.00 to $36.00. They now have an “overweight” rating on the stock.
• 9/9/2026 – Dyne Therapeutics had its price target lowered by Robert W. Baird from $30.00 to $26.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – Dyne Therapeutics had its price target lowered by Royal Bank Of Canada from $35.00 to $30.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – Dyne Therapeutics was downgraded by JPMorgan Chase & Co. from “neutral” to “underweight”. They now have a $10.00 price target on the stock, down from $17.00.
• 9/8/2026 – Dyne Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $37.00 price target on the stock.
• 8/17/2026 – Dyne Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
• 8/1/2026 – Dyne Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 7/31/2026 – Dyne Therapeutics had its price target lowered by Morgan Stanley from $47.00 to $45.00. They now have an “overweight” rating on the stock.
• 7/30/2026 – Dyne Therapeutics had its price target raised by Royal Bank Of Canada from $30.00 to $35.00. They now have an “outperform” rating on the stock.
• 7/23/2026 – Dyne Therapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 7/17/2026 – Dyne Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In other Dyne Therapeutics news, CEO John Cox sold 5,658 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total value of $106,823.04. Following the completion of the sale, the chief executive officer owned 357,507 shares in the company, valued at approximately $6,749,732.16. The trade was a 1.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Douglas Kerr sold 3,745 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $24.35, for a total value of $91,190.75. Following the completion of the sale, the insider directly owned 163,854 shares of the company’s stock, valued at $3,989,844.90. The trade was a 2.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 4,150,974 shares of company stock worth $99,697,629. Insiders own 9.46% of the company’s stock.

Dyne Therapeutics, Inc is a biotechnology company focused on developing treatments for genetically driven muscle diseases. The company uses its FORCE platform, which is designed to deliver oligonucleotide therapeutics to skeletal muscle and other tissues by combining muscle-targeting antibodies with genetic medicines.

Dyne’s research and development programs are aimed at conditions in which the underlying genetic mutations impair muscle function. Its pipeline has included DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients with mutations amenable to exon 51 skipping.